AAOS Pens Letter to FDA Calling for Transparency of Biologic Product Data

In the following letter to the FDA, written with expertise from the AAOS Devices, Biologics, and Technology Committee, AAOS encouraged the FDA to require manufacturers to reduce ambiguity and increase publicly available regulatory information as it relates to biologic orthopaedic products.

Biologics Dashboard Enhanced for Easier Product Name Search

Ryan Pezold, MA, MBA

Navigating and tracking the wide variety of biologic treatments marketed to orthopaedic surgeons can be daunting tasks.